Novartis OTCs Spur Consumer Health Growth As Sandoz Struggles
This article was originally published in The Tan Sheet
Executive Summary
Novartis says future OTC profit growth will hinge on the strength of its core strategic nonprescription brands
You may also be interested in...
Novartis Expects Thin Strips Technology To Drive OTC Cough/Cold Sales
Novartis Consumer Health is gearing up to launch new cough/cold products using a Thin Strips dosage form this summer
Bristol Sells Its Mead Johnson Adult Nutritionals Business To Novartis
The divestiture of Mead Johnson's adult nutritionals business to Novartis Medical Nutrition will allow the Bristol-Myers Squibb division to concentrate on its infant formula franchise
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC